Angiogenesis inhibitors for the treatment of ovarian cancer

Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum, Jo Morrison

Research output: Contribution to journalArticlepeer-review


Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being developed to target specific molecular pathways. One such class of drugs inhibits angiogenesis (the development of new blood vessels), which is essential for tumour growth. It is important to establish whether the addition of these new drugs to conventional chemotherapy regimens improves survival, and what the side-effects may be.
Original languageEnglish
Pages (from-to)CD007930
JournalCochrane Database of Systematic Reviews
Issue number9
Publication statusPublished - 2011


Dive into the research topics of 'Angiogenesis inhibitors for the treatment of ovarian cancer'. Together they form a unique fingerprint.

Cite this